VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as Chief Financial Officer and Head of Business Development, effective immediately. Mr. McNulty is an accomplished financial executive in the biopharmaceutical and medical device field, with a strong background in licensing transactions, capital markets and financing strategy, and public company corporate finance.
“We are delighted to have Chris join VBI during this very exciting time in the company’s growth trajectory,” said Jeff Baxter, VBI’s President and CEO. “Chris brings extensive experience working in the U.S. capital markets, and we believe his experience in biotech transactions will help the company achieve our objectives of maximizing shareholder value over time. We look forward to Chris’s financial leadership as we remain committed to addressing large, unmet medical needs in both infectious disease and immuno-oncology.”“I am thrilled to join VBI’s experienced executive team at this transformational time,” said Mr. McNulty. “I look forward to leading the finance and business development teams, particularly as the Company prepares for several key clinical milestones expected throughout the next year.”
Mr. McNulty’s background spans two decades of financial and business development experience across the pharmaceutical, biotechnology, and medical device industries. Prior to joining VBI, he served as Chief Financial Officer and Senior Vice President, Business Development and Investor Relations, of Invivo Therapeutics. He also served as the Senior Director of Business Development for Repligen Corporation, where he spearheaded the acquisition of Novozymes Biopharma Sweden in 2011. Other prior management positions include Director, Corporate Development at Seventh Sense Biosystems, and Associate Director, Business Development at Genzyme Corporation.
Mr. McNulty holds B.S. and M.Eng. degrees from the Massachusetts Institute of Technology, as well as an M.B.A. from Harvard Business School.